EUSA Pharma
Gaël Le Rouzo has a strong background in market access and pricing, with experience in various leadership roles. Gaël is currently the Head of Market Access at Neuraxpharm since 2023. Prior to this, they worked at EUSA Pharma for several years, serving as the Global Market Access and Pricing Director, Global Market Access Director, Regional Business Director for Emerging Markets, and Oncology Scientific & Market Access Manager. Le Rouzo also held the position of Business Director at Jazz Pharmaceuticals from 2015 to 2017. Earlier in their career, they worked at EUSA Pharma as the Commercial Director and International Sales Director for Asia & North Africa. Before that, they were a Business Development Manager at 4 Front Research and a Sales Director at CIT. Le Rouzo began their career at Rhône-Poulenc as a Sales & Marketing Manager.
Gaël Le Rouzo obtained an advanced degree in Finance, English, Economics, and Marketing from NEOMA Business School, where they studied from 1992 to 1996. Gaël also completed a European Market Access University Diploma in Market Access at Université Paris Cité from 2017 to 2018.
This person is not in any offices
EUSA Pharma
1 followers
We are committed to transforming the lives of people affected by cancer or rare disease, globally. We continuously strive to uncover opportunities which address gaps across adult and paediatric care. Helping the people with few or no options available is at the heart of everything we do. EUSA Pharma is part of Recordati Rare Diseases (recordatirarediseases.com), the business unit dedicated to rare disease in the Recordati group. Recordati has a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. More information can be found in the press release: https://www.recordati.com/resources/Pubblicazione/___58a6bc05f57c4861aae203c930cd1682_/eusa-closing-pr.pdf We see a need. We work together. We don’t give up.